drugset / Trial / NCT05546515
Suvorexant for Opioid/Stimulant Co-use
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Suvorexant | Small molecule | 20 mg | — |